Abstract
BackgroundLimited response to programmed death ligand-1 (PD-L1)/programmed death 1 (PD-1) immunotherapy is a major hindrance of checkpoint immunotherapy in non-small cell lung cancer (NSCLC). The abundance of PD-L1 on the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have